Q4 2025 Avanos Medical Inc Earnings Call Transcript
Key Points
- Avanos Medical Inc (AVNS) delivered full-year net sales of $701 million, exceeding revised expectations.
- The Specialty Nutrition Systems portfolio grew over 8% organically, reaffirming market-leading positions.
- The radiofrequency ablation business posted double-digit organic growth, contributing to overall success.
- Successful execution of tariff mitigation strategies is expected to benefit financial performance in 2026.
- The Nexus Medical acquisition has been integrated successfully, contributing positively to growth.
- Tariffs significantly impacted profitability in 2025, with ongoing challenges expected in 2026.
- The surgical pain business experienced a year-over-year decline due to delayed NOPAIN Act implementation.
- The Game Ready portfolio posted similar revenue levels year-over-year, indicating stagnation.
- Operating profit for the Specialty Nutrition Systems segment decreased by 100 basis points due to tariffs.
- The hyaluronic acid and IV therapy product lines declined over 35% due to divestitures and strategic exits.
Good morning ladies and gentlemen, and welcome to Avanos' fourth-quarter 2025 earnings conference call. (Operator Instructions) Also note that this call is being recorded on February 24, 2026. I would now like to turn the conference over to Jason Pickett, Vice President, Corporate Finance and Treasurer. Please go ahead.
Good morning, everyone, and thanks for joining us. It's my pleasure to welcome you to Avanos' 2025 fourth-quarter and full-year earnings conference call. Presenting today will be Dave Pacitti, CEO; and Scott Galovan, Senior Vice President and CFO.
Dave will review our fourth-quarter and full-year results and the current business environment. Scott will share additional details regarding these topics and provide our 2026 planning assumptions. We will finish the call with Q&A. A presentation for today's call is available on the Investor section of our website avanos.com.
As a reminder, our comments today contain forward-looking statements
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
